Find Reports
Select Report Type
Reimbursement Review
Displaying 1226 - 1250 of 1426
Please scroll or swipe to the right to view the full content.
| Title | Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|---|
| Ticagrelor | Brilinta | Ticagrelor | Acute Coronary Syndromes | Cancelled | SR0203-000 | ||||
| Telmisartan / Amlodipine | Twynsta | Telmisartan / Amlodipine | Hypertension | Cancelled | SR0207-000 | ||||
| Buprenorphine transdermal patc... | BuTrans | Buprenorphine transdermal patch | Pain, persistent (moderate intensity) | Cancelled | SR0211-000 | ||||
| Oxycodone / naloxone | Targin | Oxycodone / naloxone | Pain, Moderate to severe and relief of opioid-induced constipation | Cancelled | SR0219-000 | ||||
| Teriparatide (rDNA origin) inj... | Forteo | Teriparatide (rDNA origin) injection | Osteoporosis | Withdrawn | SR0065-000 | ||||
| Ramipril/hydrochlorothiazide | Altace HCT | Ramipril/hydrochlorothiazide | Hypertension | Cancelled | SR0083-000 | ||||
| Tramadol hydrochloride | Zytram XL | Tramadol hydrochloride | Pain, acute | Withdrawn | SR0086-000 | ||||
| Atomoxetine hydrochloride | Strattera | Atomoxetine hydrochloride | Attention deficit hyperactivity disorder | N/A | Complete | SF0085-000 | |||
| Efalizumab | Raptiva | Efalizumab | Psoriasis, moderate to severe chronic plaque | N/A | Complete | SF0102-000 | |||
| Sodium oxybate | Xyrem | Sodium oxybate | Narcolepsy | Withdrawn | SR0107-000 | ||||
| Maraviroc | Celsentri | Maraviroc | HIV | Withdrawn | SR0113-000 | ||||
| empagliflozin | Jardiance | empagliflozin | Chronic kidney disease | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0040-000 | |||
| setmelanotide | Imcivree | setmelanotide | Weight management for pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0041-000 | |||
| efgartigimod alfa | Vyvgart | efgartigimod alfa | Chronic inflammatory demyelinating polyneuropathy | Pending | SR0894-000 | ||||
| tislelizumab | tislelizumab | recurrent or metastatic nasopharyngeal carcinoma | Pending | PC0399-000 | |||||
| Treanda-Rituximab for Chronic ... | Treanda (in combination with rituximab) | Bendamustine hydrochloride | Chronic Lymphocytic Leukemia | Withdrawn | PC0040-000 | ||||
| dabrafenib trametinib | Tafinlar-Mekinist | dabrafenib trametinib | Advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation | Cancelled | PC0337-000 | ||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| pegcetacoplan | TBC | pegcetacoplan | Geographic atrophy secondary to age-related macular degeneration | Withdrawn | SR0810-000 | ||||
| Pharmaceutical Reviews Update ... | |||||||||
| lecanemab | Leqembi | lecanemab | Alzheimer’s disease | Suspended | SR0822-000 | ||||
| quizartinib | Vanflyta | quizartinib | acute myeloid leukemia (AML) | Active | PC0359-000 | ||||
| Onivyde for Metastatic Pancrea... | Onivyde | Nanoliposomal Irinotecan | Cancelled | PC0096-000 | |||||
| Avastin for Malignant Pleural ... | Avastin | Bevacizumab | Withdrawn | PC0100-000 | |||||
| RFA: Inlyta for Metastatic Ren... | Inlyta (RFA) | Axitinib | Metastatic Renal Cell Carcinoma | N/A | Complete | PA0001-000 |
Health Technology Review
Displaying 601 - 602 of 602
Horizon Scan
Displaying 101 - 110 of 110
Projects in Progress
Displaying 26 - 27 of 27
View All Reports
Displaying 1226 - 1250 of 2138
Please scroll or swipe to the right to view the full content.
Provisional Funding Algorithm
Displaying 76 - 81 of 81